Position in EXEL
as of Jun 30, 2026
· filed Jul 15, 2026
Position Value
$552,207
+$132,400 QoQ
Shares Held
10,149
+3.7% QoQ
Ownership
0.004%
of shares outstanding
% of Portfolio
0.05%
of 13F equity value
Holder Rank
#414
of 751 holders
Holding Since
Dec 2025
3 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in EXEL Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026WADDELL & ASSOCIATES, LLC holds $4,814,646 across 11 Biotechnology names. EXEL ranks #4 (11.5% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | INCY |
Incyte Corp
|
10,470 | $1,186,879 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
|
1,548 | $965,239 | |
| 3 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
1,235 | $613,461 | |
| 4 | EXEL |
Exelixis, Inc.
This page
|
10,149 | $552,207 | |
| 5 | BMRN |
Biomarin Pharmaceutical Inc
|
5,470 | $312,993 | |
| 6 | RPRX |
Royalty Pharma plc
|
5,486 | $307,600 | |
| 7 | FTRE |
Fortrea Holdings Inc.
|
14,580 | $253,692 | |
| 8 | RVMD |
Revolution Medicines, Inc.
|
1,193 | $223,425 |
All Filings in EXEL
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $552,207 | 10,149 | Shares | Sole | 2026-07-15 | |
| 2026-03-31 | $419,807 | 9,788 | Shares | Sole | 2026-05-11 | |
| 2025-12-31 | $503,694 | 11,492 | Shares | Sole | 2026-02-11 | |
| No filing history on record for this holder in this stock. | ||||||